We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00558350
Recruitment Status : Completed
First Posted : November 14, 2007
Last Update Posted : March 15, 2012
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Brief Summary:
Inflammatory reaction in different compartments of the body may have a negative effect on outcome. This study assesses the inflammatory reaction systemically, intrapulmonary and intrapleural by measuring different cytokines. Patients with lung cancer undergoing lobectomy or segmentectomy are included in the study. Hypothesis: The inflammatory reaction in the pleural space is high compared to the systemic and intrapulmonary ones.

Condition or disease
Lung Neoplasms

Study Type : Observational
Actual Enrollment : 15 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Systemic, Intrapulmonary and Pleural Inflammatory Reaction in Patients Undergoing Thoracic Surgery
Study Start Date : April 2007
Primary Completion Date : June 2011
Study Completion Date : June 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

lobectomy / segmentectomy in patients with lung cancer

Primary Outcome Measures :
  1. Cytokine levels in blood, bronchial lavage fluid and pleural fluid [ Time Frame: 2 years ]
  2. Correlation between cytokine levels and pulmonary morbidity [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Comparison of this collective with transthoracic esophagectomies and evaluation of the inflammatory reactions (esophageal collective registered:NCT00512265) [ Time Frame: 4 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
all patients undergoing lobectomy or segmentectomy for lung cancer at a single institution

Inclusion Criteria:

  • elective lobectomy
  • elective segmentectomy
  • 20-90 years
  • informed consent given

Exclusion Criteria:

  • emergency operations
  • pneumonectomy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00558350

University Hospital Basel
Basel, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Principal Investigator: Urs Zingg, MD University Hospital, Basel, Switzerland

Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT00558350     History of Changes
Other Study ID Numbers: 68/07
First Posted: November 14, 2007    Key Record Dates
Last Update Posted: March 15, 2012
Last Verified: March 2012

Keywords provided by University Hospital, Basel, Switzerland:
inflammatory reaction

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes